Anti-Bcl 11a (B-cell CLL/Lymphoma 11A, EVI9, Ecotropic Viral Integration Site 9, CTIP1, CTIP-1, COUP

The B cell leukemia 11A protein (BCL11A/Evi9/CTIP1) has been implicated in hematopoietic cell development and malignancies. BCL11A is a transcriptional repressor that binds directly to a GC-rich motif and is also recruited to a promoter template via interaction with the orphan nuclear receptor, chicken ovalbumin upstream promoter transcription factor II. In both cases, BCL11A-mediated transcriptional repression is only minimally reversed by trichostatin A, suggesting the possible lack of involvement of class I or II histone deacetylases. Nonetheless, chromatin immunoprecipitation assays revealed that expression of BCL11A in mammalian cells resulted in deacetylation of histones H3 and/or H4 that were associated with the promoter region of a reporter gene. BCL11A mediated transcriptional repression, as well as deacetylation of histone H3/H4 in BCL11A-transfected cells, was partially reversed by nicotinamide, an inhibitor of class III histone deacetylases such as SIRT1. SIRT1 was found to interact directly with BCL11A and was recruited to the promoter template in a BCL11A-dependent manner leading to transcriptional repression. These findings indicate a role for SIRT1 in transcriptional repression mediated by BCL11A in mammalian cells. Applications: Suitable for use in Flow Cytometry, Western Blot, Immunoprecipitation and ChIP. Other applications not tested. Recommended Dilution: Flow Cytometry: 1:10-1:1000, Western Blot: 1:1000-1:5000, Immunoprecipitation: 2-10ug/mg lysate, ChIP 1:10-1:500, Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C. For long-term storage, aliquot and store at 4°C. Do not freeze. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.